- Home
- CGEM vs MDXG Comparison
CGEM vs MDXG Comparison
Compare CGEM & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- MDXG
- Stock Information
- Founded
- CGEM 2016
- MDXG 2006
- Country
- CGEM United States
- MDXG United States
- Employees
- CGEM N/A
- MDXG N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- CGEM Health Care
- MDXG Health Care
- Exchange
- CGEM Nasdaq
- MDXG Nasdaq
- Market Cap
- CGEM 955.5M
- MDXG 1.1B
- IPO Year
- CGEM 2021
- MDXG N/A
- Fundamental
- Price
- CGEM $12.54
- MDXG $9.24
- Analyst Decision
- CGEM Strong Buy
- MDXG Strong Buy
- Analyst Count
- CGEM 7
- MDXG 5
- Target Price
- CGEM $31.67
- MDXG $12.00
- AVG Volume (30 Days)
- CGEM 537.5K
- MDXG 1.1M
- Earning Date
- CGEM 11-07-2024
- MDXG 10-30-2024
- Dividend Yield
- CGEM N/A
- MDXG N/A
- EPS Growth
- CGEM N/A
- MDXG N/A
- EPS
- CGEM N/A
- MDXG 0.52
- Revenue
- CGEM N/A
- MDXG $342,804,000.00
- Revenue This Year
- CGEM N/A
- MDXG $9.56
- Revenue Next Year
- CGEM N/A
- MDXG $9.19
- P/E Ratio
- CGEM N/A
- MDXG $18.32
- Revenue Growth
- CGEM N/A
- MDXG 10.93
- 52 Week Low
- CGEM $7.64
- MDXG $5.47
- 52 Week High
- CGEM $30.19
- MDXG $9.49
- Technical
- Relative Strength Index (RSI)
- CGEM 31.78
- MDXG 81.04
- Support Level
- CGEM $12.04
- MDXG $8.55
- Resistance Level
- CGEM $17.50
- MDXG $9.49
- Average True Range (ATR)
- CGEM 1.12
- MDXG 0.40
- MACD
- CGEM -0.36
- MDXG 0.15
- Stochastic Oscillator
- CGEM 9.15
- MDXG 96.72
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.